- Research article
- Open Access
Lentivirus mediated silencing of Ubiquitin Specific Peptidase 39 inhibits cell proliferation of human hepatocellular carcinoma cells in vitro
© Pan et al.; licensee BioMed Central. 2015
- Received: 11 December 2014
- Accepted: 23 February 2015
- Published: 19 March 2015
The Correction to this article has been published in Biological Research 2018 51:19
Ubiquitin Specific Peptidase 39 (USP39) is a 65 kDa SR-related protein involved in RNA splicing. Previous studies showed that USP39 is related with tumorigenesis of human breast cancer cells.
In the present study, we investigated the functions of USP39 in human hepatocellular carcinoma (HCC) cell line SMMC-7721. We knocked down the expression of USP39 through lentivirus mediated RNA interference. The results of qRT-PCR and western blotting assay showed that both the mRNA and protein levels were suppressed efficiently after USP39 specific shRNA was delivered into SMMC-7721 cells. Cell growth was significantly inhibited as determined by MTT assay. Crystal violet staining indicated that colony numbers and sizes were both reduced after knock-down of USP39. Furthermore, suppression of USP39 arrested cell cycle progression at G2/M phase in SMMC-7721cells. In addition, Annexin V showed that downregulation of USP39 significantly increased the population of apoptotic cells.
All our results suggest that USP39 is important for HCC cell proliferation and is a potential target for molecular therapy of HCC.
- Ubiquitin Specific Peptidase 39
- Human hepatocellular carcinoma
- Cell proliferation
- Cell cycle
Human hepatocellular carcinoma (HCC) is the most popular type of liver cancer, which is mainly caused by viral infection [1-3]. It ranks as one of the top reasons of cancer related death all over the world [4,5]. The high rate of tumor recurrence and intrahepatic metastasis lead to poor prognosis of HCC patients . To find out the molecules associated with HCC is very important for therapy of HCC .
Recently, RNA interference (RNAi) has emerged as a powerful tool to down-regulate the expression of target genes in mammalian cells and animals, especially in cancer cells . Lentiviral vectors taking small hairpin RNA (shRNA) are found capable of silencing target gene expression with high specificity, stability and efficiency in a variety of human cancer cells including HCC cells [8,9,6].
RNA splicing plays key role in eukaryotic gene expression . Mutations of splicing elements or changes of activities could affect tumor genesis and progression [11,12]. Ubiquitin Specific Peptidase 39 (USP39) is a 65 kDa SR-related protein in human cells involved in assembly of spliceosome, as well as a deubiquitinating enzyme without protease activity [13,14]. Although USP39 included the ubiquitin enzyme area but without de-ubiquitinating enzymes activity. USP39 plays an important role in the maintenance of mitotic spindle checkpoint function. The function is that it strictly controlled the activity of ubiquitin ligase. And only when all chromosomes are attached to the spindle in anaphase of mitosis, it will release the ubiquitin ligase activity . As is known, the spliceosome consists of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5 and U6, along with many non-snRNP proteins. Human USP39 protein is a tri-snRNP-specific protein, which is essential for recruitment of the tri-snRNP to the pre-spliceosome . USP39 is highly conserved, with 65% homology to the yeast Sad1p. Sad1p is involved in the assembly of U4 snRNP to U6 snRNP and splicing both in vivo and in vitro [13,14].
The gene mutation of USP39 can cause that the mutation of retinoblastoma rb1 mRNA splicing is blocked, and leading to the occurrence of pituitary adenoma . It showed that the down-regulation of USP39 gene can cause rb1 mRNA splicing abnormalities, which then leaded to downstream target genes e2f4 up-regulated in zebrafish. It is well known that e2f4 is a main regulator, it has the strong ability to cause tumor formation when it is overexpressed.
Previous studies found that down-regulation of USP39 could inhibit cell growth and colony formation of human breast cancer cells . USP39 is also involved in the proliferation of prostate cancer cells and its SUMOylation is important for its function . However, there is no report about the functions of USP39 in human hepatocellular carcinoma. In this study, taking advantage of lentivirus mediated RNAi, we inhibited the expression of USP39 in SMMC-7721 cells. We then analyzed the functions of USP39 in SMMC-7721 cell growth and colony formation. Furthermore, we checked the cell cycle progression after knock-down of USP39.
Expression of USP39 was suppressed efficiently in SMMC-7721 cells by lentivirus mediated RNAi
Down-regulation of USP39 inhibited cell proliferation and colony formation ability of SMMC-7721 cells
Down-regulation of USP39 impaired cell cycle progression of SMMC-7721 cells
Down-regulation of USP39 induced SMMC-7721 cells apoptosis
To further confirm the influence of USP39 on cell apoptosis, we used Annexin V-APC/7-AAD double staining on SMMC-7721 cells following lentivirus infection. Annexin V-APC vs 7-AAD plots from the gated cells showed the populations corresponding to viable (Annexin V-/AAD-), necrotic (Annexin V–/7-AAD+), early apoptotic (Annexin V+/7-AAD–), and late apoptotic (Annexin V+/7-AAD+) cells. The group of silencing USP39 increased the apoptotic cells (early apoptosis and late apoptosis) by 13-fold, as compared to the group of shCon (Additional file 1: Figure S1A and B). Therefore, These results demonstrated that USP39 gene interference induced a strong pro-apoptotic effect in human hepatocellular carcinoma SMMC-7721 cells. Thus, we may conclude that USP39 is involved in signaling pathways that intervene hepatocellular carcinoma cell apoptosis.
Down-regulation of USP39 altered the expression of apoptotic proteins of SMMC-7721 cells
As shown in Figure 3C, knockdown of USP39 observably caused increased percentage of SMMC-7721 cells in the sub-G1 phase which represents apoptotic cells (p < 0.001). The expression change of apoptosis genes have been detected in SMMC-7721 cells after USP39 knockdown, including Bax, Caspase 9, Caspase 3 and PARP by western blot. It showed that knockdown of USP39 resulted in a significantly increase in the expressin of Bax, Caspase 9, Caspase 3 and PARP (Additional file 2: Figure S2). These results suggested that knockdown of USP39 in SMMC-7721 cells could induce cell apoptosis via altering the expression of Bax, Caspase 9, Caspase 3 and PARP.
Human hepatocellular carcinoma (HCC) is the most popular type of liver cancer, which is mainly caused by viral infection and is the third leading cause of cancer-related death [1-3]. It ranks as one of the top reasons of cancer related death all over the world [4,5]. The high rate of tumor recurrence and intrahepatic metastasis lead to poor prognosis of HCC patients . RNAi, with the high specific and no apparent toxicity, is a promising gene therapeutic methods for the treatment of cancer in the furture . Molecular targets are needed to be discovered for the treatment of hepatocellular carcinoma.
Cell growth and colony formation are two important indexes for tumorigenesis. Our studies indicate a defect of cell growth and colony formation of HCC cells after knock-down of USP39, which is similar to previous reports of USP39 in breast cancer cells . Flow cytometry showed that down-regulation of USP39 resulted in arrest of SMMC-7721 cells at G2/M phase and more apoptosis. In consistent with our results, suppression of USP39 in MCF-7 cells leads to impaired cell cycle . In addition, flow cytometry analysis using Annexin V-APC/7-AAD was applied to confirm the influence of USP39 on cell apoptosis. Downregulation of USP39 induced a remarkable pro-apoptotic effect in human hepatocellular carcinoma SMMC-7721 cells. Therefore, we could draw the conclusion that USP39 silencing led to the proliferation inhibition in human hepatocellular carcinoma presumably as a result of the induction of apoptosis. Furthermore, western blot showed that depletion of USP39 distinctly upregulated the expression of Bax, which pertains to the Bcl-2 family of pro-apoptotic proteins , and also augmented the protein expression levels of Caspase 9, Caspase 3 and cleaved PARP that are key apoptosis-associated proteins, especially the cleaved-PARP is considered to be a marker of apoptosis [22,23]. It further confirmed that knockdown of USP39 could suppress the growth of hepatocellular carcinoma cells through inducing cell apoptosis.
Sad1, the homologue of USP39 in yeast, could control multiple checkpoints of cell cycle . Mutations of Sad1 affect both the spindle formation and function, as well as splicing [25,13]. Van Leuken et al. found that USP39 is a new factor required to maintain the spindle checkpoint and support successful cytokinesis through regulating of Aurora B mRNA splicing in mammalian cells . Aurora B is a Ser/Thr kinase and supports the assembly of a functional bipolar spindle. Silencing the Aurora B using RNAi suppresses the activity of PI3K/Akt/NF-kB signaling pathway and inhibits proliferation, migration and invasion of various carcinoma cells [26-28]. Aurora B inhibitors have the antitumor activity and some of them have been tested in clinical trials in patients with solid tumors and acute myeloid leukemia [29-31]. In USP39 depleted U2OS cells, the mRNA level of Aurora B is dramatically reduced, which leads to defection in spindle checkpoint function and cytokinesis . These evidences suggest USP39 might control cell proliferation through regulating Aurora B or other mRNA splicing.
One method to treat cancer is to induce apoptosis of cancer cells. Lv-shUSP39 infected SMMC-7721 cells showed increased sub-G1 phase cells, which are usually considered as an indicator of apoptotic fragmentation. USP39 knock-down MCF-7 cells present similar phenotype . In addition, mutations of yeast Sad1is related with yeast cell viability and deletion of Sad1 is lethal . Although lentivirus could efficiently deliver shRNA into mammalian cells and silencing USP39 in carcinoma cells, targeted gene delivery methods are need to be developed to specifically knockdown USP39 expression in tumor cells.
In conclusion, our studies indicated that suppression of USP39 through recombinant lentivirus taking shUSP39 inhibited cell proliferation and colony formation of HCC cells along with cell cycle arrest at G2/M phase. These results suggest that USP39 may be a potential target gene for treatment of HCC.
Cell lines and culture conditions
HCC cell line SMMC-7721 and human embryonic kidney cell line 293 T (HEK293T) were obtained from Cell Bank of Chinese Academy of Sciences (Shanghai, China). Both of the cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, SH30243.01B+) plus 10% fetal bovine serum (FBS, Biowest, S1810) and 100 U/ml of penicillin-streptomycin. The cells were incubated at 37°C in a humidified atmosphere of 5% CO2. All experimental researches handling human cells were carried out in compliance with the Tenets of the Declaration of Helsinki.
Lentivirus packaging and transduction
Short hairpin RNA (shRNA) targeting human USP39 gene (NM_001256725.1) was designed as following, 5′-CCTTCCAGACAACTATGAGATCTCGAGATCTCATAGTTGTCTGGAAGGTTTTT-3′. The control scrambled shRNA was 5′-GCGGAGGGTTTGAAAGAATATCTCGAGATATTCTTTCAAACCCTCCGCTTTTTT-3′. Both shRNAs were inserted into the vector pFH-L (Shanghai Hollybio, China) between restriction enzyme site NheI and PacI. The shRNA taking plasmid together with two helper plasmids, pVSVG-I and pCMV∆R8.92 (Shanghai Hollybio, China), were transfected into the HEK293T cells using Lipofectamine 2000 (Life technologies, USA). Two days after transfection, cell culture media was collected and concentrated. The recombinant lentivirus was stored at -80°C.
SMMC-7721 cells were incubated in a six-well plate at an inoculation density of 5 × 104 cells/well. The recombinant lentivirus containing media were added into the SMMC-7721 cells with a multiplicity of infection (MOI) of 30. Infection efficiency was determined through counting the numbers of GFP-positive cells under fluorescence microscope at 96 h after lentiviral infection.
Primers 5′-GCCAGCAGAAGAAAAAGAGC-3′ (forward) and 5′- GCCATTGAACTTAGCCAGGA-3′ (reverse) were designed to detect USP39 expression. Actin was used as endogenous control and primers were 5′- GTGGACATCCGCAAAGAC -3′ (forward) and 5′- AAAGGGTGTAACGCAACTA -3′ (reverse). Six days after lentiviral infection, SMMC-7721 cells were harvested and total RNA was extracted using TRIzol (Life technologies, USA) according to the manufacturer’s instructions. Single strand cDNA was obtained using M-MLV reverse transcriptase kit (Promega, USA). USP39 mRNA level was then measured by qRT-PCR with SYBR master mixture (Applied Biosystems) on BioRad Connect Real-Time PCR platform. The 20 μl PCR reaction mixture was: 10 μL 2XSYBR premix ex taq, 0.8 μLprimers (2.5 μM), 5 μL cDNA and 4.2 μL ddH2O. The detailed PCR program was: initial denaturation at 95°C for 1 min; denaturation 95°C, 5 s; annealing extension of 60°C, 20 s (a total of 40 cycles). The absorbance values were read at the extension stage. Fold changes in expression have been calculated using the 2-ΔΔCt method. Experiments were performed at least three times.
Six days after lentiviral infection, SMMC-7721 cells were collected, washed with ice-cold PBS and lysed in 2× SDS sample buffer (100 mM Tris-Hcl (pH 6.8), 10 mM EDTA, 4% SDS, 10% Glycine). Equal amount of protein samples (30 μg) were run on the 10% SDS-PAGE gel at 50 V for 3 h. The proteins were then transferred to polyvinylidene fluoride (PVDF) membrane at 300 mA for 1.5 h. The membrane was blocked by 1% bovine serum albumin (BSA) in TBST at RT for 1 h and incubated with primary antibodies, mouse anti-USP39 (1:100, Sigma Aldrich, SAB1407042) , rabbit anti-PARP (1: 1000, Cell Signaling Technology, #9542), rabbit anti-Caspase 3 (1: 500, Cell Signaling Technology, #9661), rabbit anti- Caspase 9 (1:1000, Proteintech Group Inc., 10380-1-AP), rabbit anti-Bax (1: 500, Cell Signaling Technology, #2774) and rabbit anti-GAPDH (1:100,000, Proteintech Group Inc., 10494-1-AP) overnight at 4°C. After washed by TBST, membranes were incubated with horseradish peroxidase conjugated goat anti-mouse (1:5,000, Santa Cruz, SC-2005) and goat anti-rabbit (1:5,000, Santa Cruz, SC-2054) secondary antibodies for 2 h at room temperature. The membrane was washed by TBST and signals were detected by enhanced chemiluminescence kit (Pierce).
Cell proliferation assay
Lentiviral infected SMMC-7721 cells were seeded in 96-well plates at an inoculation density of 3,000 cells/well. At different time points after incubation (1, 2, 3, 4 and 5 days), MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) solution was added to each well and incubated at 37°C for 4 h. Then 100 μL acidic isopropanol (10% SDS, 5% isopropanol and 0.01 mol/L HCl) was added into each well after the medium were carefully removed. Plates were then read at a wavelength of 595 nm. Experiments were performed at least three times.
Colony formation assay
Lentiviral infected SMMC-7721 cells were seeded in 6-well plate at an initial density of 600 cells/well. Cells were cultured in 5% CO2 incubator for 8 days at 37°C. After wash by ice-cold PBS and fixation with 4% PFA, crystals purple staining was performed according to the instruction.
Cell cycle assay
Lentiviral infected SMMC-7721 cells were seeded in 6 cm dishes at initial density of 80,000 cells/dish. After incubation at 37°C for 40 h, the cell confluence reached ~80%. SMMC-7721 cells were then collected, washed in cold PBS and fixed with pre-cold 75% ethanol. After digestion using RNase, the cells were stained with Propidium iodide (PI). Cell cycle distribution was then analyzed by using a flow cytometer (BD Biosciences). Experiments were performed at least three times.
Cell apoptosis assay by flow cytometry
SMMC-7721 cells were subjected to three different treatments (Con, Lv-shCon, and Lv-shUSP39). After 96 h of incubation, cells were washed by PBS and re-seeded in 6 cm dishes at a density of 8 × 104 cells/dish before detection. After 48 h, the cells were collected, washed with PBS for three times and subjected to Annexin V-APC/7-AAD double staining according to the instruction of Apoptosis Assays Kit (KeyGEN Biotech, Nanjing, China). Flow cytometry analysis was performed on FACS caliber II sorter and Cell Quest FACS system (BD Biosciences, USA).
Comparisons between groups were done using paired Student’s t test, and differences were considered statistically significant at P < 0.05. Data were presented as mean ± standard deviation (SD) of three independent experiments.
This study was also reviewed and approved by the Institutional Review Board of Eastern Hepatobiliary Hospital.
We greatly acknowledge the financial support from the Innovation Program of Shanghai Municipal Education Commission (grant no. 12ZZ077).
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. doi:10.1053/j.gastro.2011.12.061.View ArticlePubMedPubMed CentralGoogle Scholar
- Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver cancer. 2012;1(3–4):226–37. doi:10.1159/000343837.View ArticlePubMedPubMed CentralGoogle Scholar
- El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72–8.View ArticlePubMedGoogle Scholar
- Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Official Pub International Cancer Imaging Soc. 2012;12:79–88. doi:10.1102/1470-7330.2012.0011.Google Scholar
- Cucchetti A, Zanello M, Cescon M, Ercolani G, Del Gaudio M, Ravaioli M, et al. Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years. Ann Surg Oncol. 2011;18(6):1630–7. doi:10.1245/s10434-010-1463-8.View ArticlePubMedGoogle Scholar
- Hwang LH. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci. 2006;13(4):453–68. doi:10.1007/s11373-006-9085-7.View ArticlePubMedGoogle Scholar
- Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567):550–3. doi:10.1126/science.1068999.View ArticlePubMedGoogle Scholar
- Nishitsuji H, Ikeda T, Miyoshi H, Ohashi T, Kannagi M, Masuda T. Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infec Institut Pasteur. 2004;6(1):76–85.View ArticleGoogle Scholar
- Follenzi A, Gupta S. The promise of lentiviral gene therapy for liver cancer. J Hepatol. 2004;40(2):337–40.View ArticlePubMedGoogle Scholar
- Valadkhan S. The spliceosome: caught in a web of shifting interactions. Curr Opin Struct Biol. 2007;17(3):310–5. doi:10.1016/j.sbi.2007.05.001.View ArticlePubMedGoogle Scholar
- Liu S, Cheng C. Alternative RNA splicing and cancer. Wiley Inter Disc Rev RNA. 2013;4(5):547–66. doi:10.1002/wrna.1178.View ArticleGoogle Scholar
- Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci. 2006;119(Pt 13):2635–41. doi:10.1242/jcs.03053.View ArticlePubMedGoogle Scholar
- Lygerou Z, Christophides G, Seraphin B. A novel genetic screen for snRNP assembly factors in yeast identifies a conserved protein, Sad1p, also required for pre-mRNA splicing. Mol Cell Biol. 1999;19(3):2008–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Makarova OV, Makarov EM, Luhrmann R. The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J. 2001;20(10):2553–63. doi:10.1093/emboj/20.10.2553.View ArticlePubMedPubMed CentralGoogle Scholar
- van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH. Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle. 2008;7(17):2710–9. doi:6553 [pii].View ArticlePubMedGoogle Scholar
- Liu S, Rauhut R, Vornlocher HP, Luhrmann R. The network of protein-protein interactions within the human U4/U6.U5 tri-snRNP. RNA. 2006;12(7):1418–30. doi:10.1261/rna.55406.View ArticlePubMedPubMed CentralGoogle Scholar
- Rios Y, Melmed S, Lin S, Liu NA. Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet. 2011;7(1):e1001271. doi:10.1371/journal.pgen.1001271.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang H, Ji X, Liu X, Yao R, Chi J, Liu S, et al. Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro. Oncol Rep. 2013;30(6):2871–7. doi:10.3892/or.2013.2798.View ArticlePubMedGoogle Scholar
- Wen D, Xu Z, Xia L, Liu X, Tu Y, Lei H, et al. Important role of SUMOylation of Spliceosome factors in prostate cancer cells. J Proteome Res. 2014;13(8):3571–82. doi:10.1021/pr4012848.View ArticlePubMedGoogle Scholar
- Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng. 2006;23(1):17–34. doi:S1389-0344(06)00003-7 [pii] 10.1016/j.bioeng.2006.01.002.View ArticlePubMedGoogle Scholar
- Lucken-Ardjomande S, Martinou JC. Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane. C R Biol. 2005;328(7):616–31. doi:S1631-0691(05)00090-9 [pii] 10.1016/j.crvi.2005.05.002.View ArticlePubMedGoogle Scholar
- Bao W, Liu R, Wang Y, Wang F, Xia G, Zhang H, et al. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int J Nanomedicine. 2015;10:557–66. doi:10.2147/IJN.S75090 ijn-10-557 [pii].PubMedPubMed CentralGoogle Scholar
- Agarwal A, Mahfouz RZ, Sharma RK, Sarkar O, Mangrola D, Mathur PP. Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes. Reprod Biol Endocrinol. 2009;7:143. doi:10.1186/1477-7827-7-1431477-7827-7-143 [pii].View ArticlePubMedPubMed CentralGoogle Scholar
- Allen JB, Zhou Z, Siede W, Friedberg EC, Elledge SJ. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev. 1994;8(20):2401–15.View ArticlePubMedGoogle Scholar
- Hagan I, Yanagida M. The product of the spindle formation gene sad1+ associates with the fission yeast spindle pole body and is essential for viability. J Cell Biol. 1995;129(4):1033–47.View ArticlePubMedGoogle Scholar
- Chile SA, Ray KB, Shaikh S, Rajagopal V, Rao HS, Ramana V, et al. Evaluation of target mRNA cleavage by aurorakinase B specific siRNA in prostate and hepatic cancer cells and its therapeutic potential in mouse models of liver cancer. Indian J Exp Biol. 2014;52(10):943–51.PubMedGoogle Scholar
- Zhou LD, Xiong X, Long XH, Liu ZL, Huang SH, Zhang W. RNA interference-mediated knockdown of Aurora-B alters the metastatic behavior of A549 cells via modulation of the phosphoinositide 3-kinase/Akt signaling pathway. Oncology Lett. 2014;8(5):2063–8. doi:10.3892/ol.2014.2464.View ArticleGoogle Scholar
- Zhu LB, Jiang J, Zhu XP, Wang TF, Chen XY, Luo QF, et al. Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-kappaB signaling pathway. Int J Clin Exp Pathol. 2014;7(7):3984–91.PubMedPubMed CentralGoogle Scholar
- Moreno L, Marshall L, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q et al. A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) in children and adolescents with solid tumours: A Cancer Research UK study. Clin Cancer Res. 2014. doi:10.1158/1078-0432.CCR-14-1592.Google Scholar
- Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013;13(5):559–67. doi:10.1016/j.clml.2013.03.019.View ArticlePubMedPubMed CentralGoogle Scholar
- Schoffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer. 2011;47(15):2256–64. doi:10.1016/j.ejca.2011.07.008.View ArticlePubMedGoogle Scholar